18.07.2017 20:12:00
|
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AngioDynamics, Inc. (ANGO)
NEW YORK, July 18, 2017 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AngioDynamics, Inc. ("AngioDynamics" or the "Company") (NASDAQ: ANGO). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/ango.
The investigation concerns whether AngioDynamics and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On July 17, 2017, after-market hours, AngioDynamics revealed that its auditor has identified a material weakness in its internal control over financial reporting as of May 31, 2016 as the Company did not design and maintain effective internal controls over the accounting for the annual goodwill impairment test, and that specifically, AngioDynamics lacked effective controls to carefully review the cash flow projections and significant valuation model assumptions used in the goodwill impairment test as of December 31, 2015. Following this news, AngioDynamics stock has dropped as much as $1.24 per share, or 7.64%, during intraday trading on July 18, 2017.
If you are aware of any facts relating to this investigation, or purchased shares of AngioDynamics, you can assist this investigation by visiting the firm's site: www.bgandg.com/ango. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com
View original content with multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-angiodynamics-inc-ango-300490114.html
SOURCE Bronstein, Gewirtz & Grossman, LLC
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu AngioDynamics Inc.mehr Nachrichten
01.01.25 |
NASDAQ Composite Index-Wert AngioDynamics-Aktie: So viel hätten Anleger mit einem Investment in AngioDynamics von vor 5 Jahren verloren (finanzen.at) | |
25.12.24 |
NASDAQ Composite Index-Titel AngioDynamics-Aktie: So viel Verlust hätte eine AngioDynamics-Investition von vor 3 Jahren eingebracht (finanzen.at) | |
24.12.24 |
Pluszeichen in New York: NASDAQ Composite klettert zum Handelsende (finanzen.at) | |
24.12.24 |
Zuversicht in New York: NASDAQ Composite-Anleger greifen am Nachmittag zu (finanzen.at) | |
24.12.24 |
Freundlicher Handel: NASDAQ Composite-Anleger greifen am Dienstagmittag zu (finanzen.at) | |
24.12.24 |
Erste Schätzungen: AngioDynamics mit Zahlen zum abgelaufenen Quartal (finanzen.net) | |
19.12.24 |
Gute Stimmung in New York: NASDAQ Composite-Anleger greifen nachmittags zu (finanzen.at) | |
18.12.24 |
NASDAQ Composite Index-Titel AngioDynamics-Aktie: So viel hätten Anleger an einem AngioDynamics-Investment von vor einem Jahr verdient (finanzen.at) |
Analysen zu AngioDynamics Inc.mehr Analysen
Aktien in diesem Artikel
AngioDynamics Inc. | 8,70 | 0,58% |